Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Better Bull Market Buy: Novavax vs. Pfizer


It's official: The S 500 is in a bull market after reaching a new all-time high last month. The index actually has been in this positive market phase ever since it started recovering from its bear market low about 16 months ago -- and since bull markets generally last longer than bear markets, investors should have plenty of time to benefit from this one.

How to get the most out of a bull market? By investing in stocks with solid growth prospects. That's because these environments usually support growth companies as well as those that are ramping up for a new wave of growth ahead. Today, the market offers plenty of opportunities, but Motley Fool contributors Adria Cimino and Keith Speights have zeroed in on two compelling healthcare players: biotech company Novavax (NASDAQ: NVAX) and big pharma (NYSE: PFE). So which makes the better bull market buy now?

Image source: Getty Images.

Continue reading


Source Fool.com

Pfizer Inc. Stock

€25.85
0.040%
There is nearly no change for the Pfizer Inc. stock today. Compared to yesterday it only changed by €0.010.
With 31 Buy predictions and 4 Sell predictions Pfizer Inc. is one of the favorites of our community.
With a target price of 41 € there is a hugely positive potential of 58.61% for Pfizer Inc. compared to the current price of 25.85 €.
Like: 0
Share

Comments